IDEAYA, Servier's Uveal Melanoma Trial Data Signals Potential First-Line Shift

Event summary

  • IDEAYA Biosciences and Servier announced positive topline results from the Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib for first-line HLA-A*02:01-negative metastatic uveal melanoma.
  • The combination demonstrated a statistically significant improvement in median progression-free survival (PFS) of 6.9 months versus 3.1 months with investigator choice therapy (ICT) (HR: 0.42; p < 0.0001).
  • The combination achieved a 37.1% overall response rate (ORR) compared to 5.8% with ICT (p < 0.0001), including 5 complete responses.
  • IDEAYA plans to submit an NDA to the FDA in H2'26, potentially seeking accelerated approval.
  • The trial enrolled 313 patients as of January 23, 2026, with the ICT arm composed of 76% ipilimumab plus nivolumab and 24% pembrolizumab.

The big picture

The OptimUM-02 results represent a significant advancement in the treatment of HLA-A*02:01-negative metastatic uveal melanoma, a rare cancer with limited therapeutic options. This success validates IDEAYA’s precision medicine approach and strengthens its partnership with Servier, which is expanding its oncology portfolio. The trial’s design, utilizing ICT as a control, highlights the unmet need and potential for disruptive therapies in this niche market, but also introduces complexities in demonstrating comparative effectiveness.

What we're watching

Regulatory Risk
The FDA’s accelerated approval pathway for darovasertib combination will hinge on the maturity of the overall survival (OS) data and the strength of the PFS benefit, potentially impacting commercial timelines.
Competitive Landscape
The adoption rate of darovasertib combination will be influenced by the continued performance and pricing of existing therapies like ipilimumab/nivolumab and pembrolizumab, particularly given the trial’s ICT arm composition.
Market Access
Given the rarity of HLA-A*02:01-negative mUM, IDEAYA and Servier will need to demonstrate a compelling value proposition to payers to ensure broad market access and reimbursement for the combination therapy.

Related topics

Pharmaceuticals Biotechnology Precision Medicine